Sensient Pharmaceutical announces Spectrablend MB-H

Published: 27-May-2014
Ingredients Pharmaceutical

Film coating system combines moisture protection with improved ease of swallowing


St Louis, Missouri, US-based Sensient Pharmaceutical, a business unit of Sensient Technologies Corporation, has introduced Spectrablend MB-H, a film coating system that combines moisture protection with improved ease of swallowing.

The company says Spectrablend MB-H can extend product shelf life by minimising the effects of moisture and its degrading effect on product stability and visual appearance. It delivers a smoother, softer surface, making it easier to swallow, and offers improved packaging ease.

'Spectrablend MB-H provides a more label-friendly, moisture-protective coating compared with earlier systems,' says Steve Strickland, General Manager of Sensient Pharmaceutical.

'Perhaps more important is its ability to improve ease of swallowing, which can offer manufacturers a means to improve the consumer appeal of their products and provide for competitive advantage.'

Sensient Pharmaceutical has 35 locations worldwide and is a global leader in coating systems, brand-defining colour and flavour solutions, and enhanced product performance for the pharmaceutical and nutraceutical markets.

  • Companies:
  • Sensient Technologies
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Using FTIR and NIR spectroscopy in process control

Read more
FTIR technology has long been used for sample identification for quality control of incoming raw materials and release of finished goods. Brian Cheng, Sensient Pharmaceuticals, looks at recent advancements in which FTIR and NIR are being applied to product development

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Using FTIR and NIR spectroscopy in process control

FTIR technology has long been used for sample identification for quality control of incoming raw materials and release of finished goods. Brian Cheng, Sensient Pharmaceuticals, looks at recent advancements in which FTIR and NIR are being applied to product development
Ingredients

Sensient to build colour and flavour facility in South Africa

Reinforces position in African market
Ingredients

Sensient reports record revenue and operating income for 2011

Driven by Flavour & Fragrances Group
Ingredients

Sensient Technologies third quarter results reach new high

Colour and flavours set new Q3 records for revenue and operating income
Drug Delivery

The colouration of tablets and capsules

Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
Ingredients

Sensient sets up new business

US-based Sensient Technologies has set up a new business as part of the Sensient Colour Group to take on the pharma activities of Warner Jenkinson.
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Subscribe now